Attached files

file filename
EX-31.2 - EXHIBIT 31.2 - ACELRX PHARMACEUTICALS INCex_106680.htm
EX-31.1 - EXHIBIT 31.1 - ACELRX PHARMACEUTICALS INCex_106679.htm
EX-23.1 - EXHIBIT 23.1 - ACELRX PHARMACEUTICALS INCex_106678.htm
EX-21.2 - EXHIBIT 21.2 - ACELRX PHARMACEUTICALS INCex_106677.htm
EX-10.20 - EXHIBIT 10.20 - ACELRX PHARMACEUTICALS INCex_106745.htm
10-K - FORM 10-K - ACELRX PHARMACEUTICALS INCacrx20171231_10k.htm

Exhibit 32.1

 

CERTIFICATION

 

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Vincent J. Angotti, Chief Executive Officer of AcelRx Pharmaceuticals, Inc. (the “Company”), and Raffi M. Asadorian, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:

 

1.

The Company’s Annual Report on Form 10-K for the period ended December 31, 2017, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and

 

2.

The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

In Witness Whereof, the undersigned have set their hands hereto as of the 8th day of March 2018.

 

     

/s/ Vincent J. Angotti

 

/s/ Raffi M. Asadorian

Vincent J. Angotti

Chief Executive Officer

 

Raffi M. Asadorian

Chief Financial Officer

 

“This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of AcelRx Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.”